Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro.

スポンサーリンク

概要

• 論文の詳細を見る

• EG626 (oxagrelate), a specific inhibitor of cyclic AMP phosphodiesterase, produced in vitro a concentration-dependent inhibition of platelet aggregation induced by collagen and ADP in human platelets. When adenosine was added to the platelet rich plasma (PRP) in the presence of a threshold concentration of EG626, the potency of adenosine in inhibiting platelet aggregation was markedly potentiated. This potentiating effect of EG626 proved to be synergistic, but not additive and was accompanied by a marked accumulation of cyclic AMP in the platelets. The antiaggregating and cyclic AMP increasing activities of adenosine were little affected by S-(p-nitrobenzyl)-6-thioguanosine (6TG), an uptake inhibitor of adenosine, or 2'-deoxycoformycin, an inhibitor of adenosine deaminase. The incorporation of adenosine into platelets was abolished by 6TG. These observations indicate that incorporation of adenosine into platelets is not required for inhibition of aggregation or an increase in cyclic AMP and that the site of action of adenosine is probably extracellular. It also appears that the synergistic action by EG626 is not the result of an inhibition of adenosine uptake and/or adenosine deaminase. This speculation is supported in part by the finding that EG626 also potentiates the antiaggregating activity of 2-chloroadenosine. Antiaggregating activity of prostaglandin E<SUB>1</SUB>, an activator of adenylate cyclase, was markedly potentiated in combination with EG626. Dibutyryl cyclic AM P showed a time-dependent inhibition of the platelet aggregation, and the inhibitory action was markedly potentiated by EG626. Qualitatively similar results were obtained with another phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine (IBMX). All these data suggest that the synergistic potentiation of the antiaggregating activity of adenosine by EG626 might be due to the synergistic accumulation of cyclic AMP in the platelets. This action is mediated through activation of adenylate cyclase by adenosine in combination with the inhibition of cyclic AMP phosphodiesterase by EG626.

• 公益社団法人 日本薬理学会の論文

著者

• Azuma Hiroshi

  Institute For Medical And Dental Engineering Tokyo Medical And Dental University

• Yamakado Toshiyuki

  Department of Pharmacology, Mie university School of Medicine

• Yamakado Toshiyuki

  Department Of Pharmacology Mie University School Of Medicine

• Takashima Yoshimi

  Institute For Medical And Dental Engineering Tokyo Medical And Dental University

• Ishikawa Masayuki

  Institute For Medical And Dental Engineering Tokyo Medical And Dental University

関連論文

• EDHF-induced relaxation is increased in the peripheral resistant vessels during pregnancy of the rat(Session21 Peninatology6)
• PHARMACOLOGICAL PROPERTIES OF A NOVEL QUINAZOLINONE DERIVATIVE, 3-(2-CHLOROPHENYL)-6-ETHOXYCARBONYL-5,7-DIMETHYL-2-(N-METHYLCARBAMOYLOXYMETHYL)-4(3H)-QUINAZOLINONE (EG1088) : MECHANISM OF VASODILATING ACTION
• STRUCTURE-ACTIVITY RELATIONSHIPS AND PHARMACOLOGICAL PROPERTIES OF A NEW HYPOTENSIVE AGENT (EG 1088)
• A NOVEL REGULATION MECHANISM OF Ca^ DEPENDENT MYOSIN LIGHT CHAIN PHOSPHORYLATION OF SMOOTH MUSCLE : Blood Vessels : FREE COMMUNICATIONS (I) : PROCEEDINGS OF THE 49th ANNUAL SCIENTIFIC MEETING OF THE JAPANESE CIRCULATION SOCIETY
• EFFECTS OF 7-ETHOXYCARBONYL-6, 8-DIMETHYL-4-HYDROXYMETHYL-1(2H)-PHTHALAZINONE (EG626) ON THE SPINAL TRIGEMINAL NUCLEUS, VENTRAL POSTEROMEDIAL NUCLEUS, AND SENSORY CORTEX
• Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro.
• Augmentation of adenosine-induced relaxation response with hydralazine in aortic strips.

スポンサーリンク